Aldose Reductase Inhibitor Ameliorates Renal Vascular Endothelial Growth Factor Expression in Streptozotocin-Induced Diabetic Rats.
10.3349/ymj.2010.51.3.385
- Author:
Joong Kyung SUNG
1
;
Jang Hyun KOH
;
Mi Young LEE
;
Bo Hwan KIM
;
Soo Min NAM
;
Jae Hyun KIM
;
Jin Hee YOO
;
So Hee KIM
;
Sun Won HONG
;
Eun Young LEE
;
Ran CHOI
;
Choon Hee CHUNG
Author Information
1. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. cchung@yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Aldose reductase inhibitor;
vascular endothelial growth factor;
albumin creatinine ratio;
diabetic nephropathy
- MeSH:
Aldehyde Reductase/*antagonists & inhibitors;
Animals;
Antihypertensive Agents/therapeutic use;
Diabetes Mellitus, Experimental/*drug therapy/*metabolism;
Diabetic Nephropathies/prevention & control;
Imidazolidines/*therapeutic use;
Kidney/*drug effects/*metabolism/pathology;
Losartan/therapeutic use;
Male;
Rats;
Rats, Sprague-Dawley;
Receptors, Angiotensin/*antagonists & inhibitors;
Vascular Endothelial Growth Factor A
- From:Yonsei Medical Journal
2010;51(3):385-391
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model. MATERIALS AND METHODS: Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg.kg(-1).day(-1)) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg.kg(-1).day(-1)) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions. RESULTS: The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 +/- 11.12, 16.11 +/- 9.95, and 84.85 +/- 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group. CONCLUSION: We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.
